Licensed doses network |

Residual deviance^{a} | 162.78 | 177.54 | 209.77 |

pD | 117.98 | 106.29 | 91.61 |

Deviance information criterion (DIC) | 280.76 | 283.83 | 301.38 |

Between-study standard deviation, posterior median (95% credible interval) | 0.31 (0.17–0.45) | 0.19 (0.12–0.28) | – |

Network of patients with no previous biologic use (< 25% had previous use) |

Residual deviance^{b} | 82.10 | 82.88 | 88.85 |

pD | 59.12 | 56.3 | 52.45 |

Deviance information criterion (DIC) | 141.22 | 139.20 | 141.30 |

Between-study standard deviation, posterior median (95% credible interval) | 0.19 (0.01–0.41) | 0.14 (0.09–0.23) | – |

Network of patients with PASI score ≤ 25 |

Residual deviance^{c} | 143.89 | 152.67 | 173.06 |

pD | 99.16 | 90.58 | 79.61 |

Deviance information criterion (DIC) | 243.05 | 243.26 | 252.67 |

Between-study standard deviation, posterior median (95% credible interval) | 0.2574 (0.114–0.408) | 0.16 (0.10–0.24) | – |

Network of patients with weight ≤ 90 kg |

Residual deviance^{d} | 66.40 | 74.17 | 80.02 |

pD | 51.59 | 44.78 | 42.14 |

Deviance information criterion (DIC) | 117.99 | 118.95 | 122.16 |

Between-study standard deviation, posterior median (95% credible interval) | 0.40 (0.08–0.76) | 0.15 (0.09–0.24) | **–** |

Network of ≥ 90% white patients |

Residual deviance^{e} | 100.57 | 112.47 | 126.65 |

pD | 78.57 | 71.62 | 63.83 |

Deviance information criterion (DIC) | 179.14 | 184.09 | 190.48 |

Between-study standard deviation, posterior median (95% credible interval) | 0.311 (0.13–0.51) | 0.17 (0.10–0.25) | – |